products
We are developing products to synergistically combine the tissue-repairing benefits of human plasma or plasma derivatives with the sustained release action of chitosan, with the goal of providing both relief and long-lasting therapeutic effect.
plasma-derived
serum eye drops
Our initial product will focus on dry eye disease (DED).
There are 22 million dry eye patients in the United States and of those only 8 million are treated with only 25% reporting satisfaction with their treatment. There is a need for more effective treatments with fewer side effects.
pipeline
ECI is focused on the development of products derived from human plasma and enhanced with chitosan. We look to target conditions such as Dry Eye Disease, ophthalmic burns, chronic wounds, and mucosal membrane dryness.
From liquid eye drops to gels, ointments, specially contoured bandages, and more, our pipeline seeks to transform wound care, improve safety, and help heal.
learn more about:
our platform
Our platform leverages plasma from donated human blood and a proprietary antimicrobial molecule (form of chitosan). The tissue-repairing benefits of plasma-derived products, combined with the sustained action of chitosan, may provide relief and long-lasting therapeutic action.
patients
Patients who experience conditions such as dry eye disease, to diabetic ulcers, and wounds or burns on skin and mucous membranes, or chronic moisture may benefit from this fusion of plasma and chitosan as a forward-thinking and potent strategy to potentially address these conditions with easier access and fewer side effects.
